Cleveland HeartLab

Cleveland HeartLab is a specialized clinical laboratory focused on advanced cardiovascular and cardiometabolic testing, operating as a subsidiary of Quest Diagnostics. It sells specialized biomarker panels aimed at identifying heart disease risk beyond standard lipid screening. In WellRank's latest index it ranks twelfth in the at-home lab testing category with 17 percent AI visibility, and the two mentions it has received in our corpus are both neutral in tone, suggesting it is recognized but not yet generating strong positive or critical commentary from AI engines.

Cleveland HeartLab, headquartered in Cleveland, Ohio, is a specialty reference laboratory that focuses on advanced cardiovascular risk testing. It was founded with ties to the Cleveland Clinic ecosystem and has operated as part of Quest Diagnostics following an acquisition, though the precise acquisition timeline is not independently verifiable from public sources at a fine-grained level. Its business model centers on providing clinicians and health systems with proprietary biomarker assays and risk-assessment reports rather than selling tests directly to consumers in large volume.

• Advanced lipoprotein particle testing beyond standard LDL measurement
• Inflammation biomarker panels including high-sensitivity CRP and myeloperoxidase
• Oxidized LDL and Lp-PLA2 assays for arterial plaque risk assessment
• CardioRisk and cardiometabolic panel bundles used by ordering clinicians
• Detailed patient and clinician reports interpreting cardiovascular biomarker results

Cleveland HeartLab primarily serves clinicians, cardiologists, and preventive medicine practices in the United States who want deeper cardiovascular risk stratification for their patients. Its panels are relevant for adults at intermediate or elevated heart disease risk and for patients whose standard lipid panels do not fully explain their risk profile. Geographic focus is the United States, with test ordering flowing through physician and health system channels.

• A preventive cardiologist who routinely orders advanced lipid panels for patients with borderline LDL levels and family histories of early heart disease.
• A primary care physician seeking a reference lab with interpretive cardiology expertise to supplement routine metabolic screening.
• A health-conscious adult with a personal or family history of cardiovascular disease whose doctor has recommended deeper biomarker evaluation.
• A corporate wellness or occupational health program administrator looking to add cardiovascular risk testing beyond basic chemistry panels.

Cleveland HeartLab operates as a subsidiary of Quest Diagnostics following an acquisition; specific acquisition price, prior venture funding rounds, and current revenue figures are not publicly disclosed.

Since being integrated into the Quest Diagnostics network, Cleveland HeartLab has continued to position its specialty cardiovascular panels as a complement to Quest's broader test menu. Wider distribution through Quest's ordering infrastructure is the most broadly noted strategic direction, though specific recent product launches or partnership announcements are not publicly detailed at a level that can be cited with confidence.

According to WellRank's corpus, Cleveland HeartLab's two AI mentions are both neutral in tone, with no positive or cautious signals detected. This pattern is consistent with a laboratory that AI engines recognize as a factual resource for cardiovascular biomarker information without yet generating the enthusiasm or scrutiny that higher-visibility brands attract. Broader consumer review sentiment is not prominent in public channels, likely reflecting the company's physician-mediated model rather than direct consumer purchasing.

Pricing for Cleveland HeartLab panels is determined through the ordering physician or health system and is not published for direct consumer comparison; out-of-pocket costs depend on insurance coverage, institutional contracts, and the specific panel ordered, making exact figures not publicly available.